{"id":"dwp14012","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL4594445","moleculeType":"Small molecule","molecularWeight":"410.42"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DWP14012 binds to and activates the glucagon-like peptide-1 (GLP-1) receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion. It also suppresses glucagon secretion and slows gastric emptying, collectively reducing postprandial and fasting blood glucose levels. The long-acting formulation allows for less frequent dosing compared to shorter-acting GLP-1 agonists.","oneSentence":"DWP14012 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:46:07.055Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06751121","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2024-02-06","conditions":"Helicobacter Pylori Infection, Helicobacter Pylori Infected Patients, Helicobacter Pylori Infected Subjects","enrollment":461},{"nctId":"NCT06508645","phase":"PHASE1","title":"Study to Evaluate the Safety/Tolerability, PK and PD After Intravenous DWJ1521 Administration in Healthy Volunteers","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-01-10","conditions":"Healthy Volunteers","enrollment":33},{"nctId":"NCT04784910","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2021-05-21","conditions":"Peptic Ulcer","enrollment":423},{"nctId":"NCT06437951","phase":"PHASE1","title":"to Evaluate the Safety/Tolerability and Pharmacokinetics, and Pharmacodynamics of DWP14012 Injection","status":"NOT_YET_RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2024-07","conditions":"Erosive Gastroesophageal Reflux Disease","enrollment":40},{"nctId":"NCT06121830","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non-Erosive Gastroesophageal Reflux Disease (NERD)","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2023-08-31","conditions":"Non-erosive Reflux Disease, Non-Erosive Gastro-Esophageal Reflux Disease, Non-Erosive Esophageal Reflux Disease","enrollment":324},{"nctId":"NCT05868967","phase":"PHASE1","title":"A Clinical Study to Investigate the Mass Balance and Biotransformation of [14C]DWP14012 in Healthy Chinese Male Subjects","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2023-02-27","conditions":"Phase 1 Study, Healthy Volunteers","enrollment":8},{"nctId":"NCT05813561","phase":"PHASE3","title":"The Efficacy and Safety of DWP14012 in Chinese Patients With Reflux Esophagitis","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2021-12-30","conditions":"Reflux Esophagitis","enrollment":332},{"nctId":"NCT05812404","phase":"PHASE1","title":"Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-10-26","conditions":"Drug Drug Interaction","enrollment":36},{"nctId":"NCT05304845","phase":"PHASE1","title":"Drug-drug Interactions Between DWP14012 and Aspirin in Healthy Subjects","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-03-21","conditions":"Drug Drug Interaction","enrollment":24},{"nctId":"NCT05574374","phase":"PHASE1","title":"Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-09-21","conditions":"Drug Drug Interaction","enrollment":36},{"nctId":"NCT04341454","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Acute or Chronic Gastritis","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2020-06-02","conditions":"Acute Gastritis, Chronic Gastritis","enrollment":327},{"nctId":"NCT05149274","phase":"PHASE1","title":"Evaluate the Pharmacokinetics and Safety of DWP14012 Tablet A and Compare Those of DWP14012 Tablet B in Healthy Subjects","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2021-10-01","conditions":"Phase 1 Study, Healthy Volunteers","enrollment":32},{"nctId":"NCT04328766","phase":"PHASE1","title":"Pharmacokinetic Interaction Between DWP14012 and DWC202005 in Healthy Volunteers","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2020-09-06","conditions":"Drug-drug Interaction","enrollment":36},{"nctId":"NCT04827472","phase":"PHASE1","title":"Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics After Intravenous DWJ1521 Administration in Healthy Adult Volunteers","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2021-01-20","conditions":"Healthy","enrollment":36},{"nctId":"NCT04888819","phase":"NA","title":"Treatment Effect According to Timing of Administration of DWP14012 40 mg","status":"UNKNOWN","sponsor":"Konkuk University Medical Center","startDate":"2021-02-01","conditions":"Erosive Esophagitis","enrollment":186},{"nctId":"NCT04613895","phase":"NA","title":"Treatment Effect According to Timing of Administration of DWP14012 40 mg","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2020-11-17","conditions":"Erosive Esophagitis","enrollment":186},{"nctId":"NCT03736369","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2018-12-13","conditions":"Erosive Esophagitis","enrollment":263},{"nctId":"NCT03184324","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 2, Therapeutic Exploratory Study)","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2017-08-28","conditions":"Erosive Gastroesophageal Reflux Disease","enrollment":211},{"nctId":"NCT04341428","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of DWP14012 on Maintaining Healing in Subjects With Healed Erosive Esophagitis","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2020-07-02","conditions":"Healed Erosive Esophagitis","enrollment":406},{"nctId":"NCT04490434","phase":"PHASE1","title":"Drug-drug Interaction Between DWP14012 and Three Different Kinds of NSAIDs","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2020-06-19","conditions":"Healthy Male Volunteers","enrollment":110},{"nctId":"NCT04185805","phase":"PHASE1","title":"Pharmacokinetics and Safety of DWP14012 Tablet A and Tablet B in Healthy Volunteers (III)","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2019-12-14","conditions":"Healthy","enrollment":24},{"nctId":"NCT04167267","phase":"PHASE1","title":"Pharmacokinetics and Safety of DWP14012 Tablet A and Tablet B in Healthy Volunteers (II)","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2019-11","conditions":"Healthy","enrollment":24},{"nctId":"NCT04003441","phase":"PHASE1","title":"Pharmacokinetics and Safety of DWP14012 Tablet A and Tablet B in Healthy Volunteers","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2019-06","conditions":"Healthy","enrollment":24},{"nctId":"NCT03574415","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP14012 After Oral Administration in Healthy Japanese, Caucasian and Korean","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2018-11-01","conditions":"Healthy Volunteers","enrollment":80},{"nctId":"NCT03487562","phase":"PHASE1","title":"Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of After Administrations of DWP14012 Alone and Combinations of DWP14012, Clarithromycin and Amoxicillin in Healthy Male Subjects","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2018-04-08","conditions":"Healthy","enrollment":48},{"nctId":"NCT03811080","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non Erosive Reflux Disease","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2019-02-07","conditions":"Non-Erosive Gastroesophageal Reflux Disease","enrollment":327},{"nctId":"NCT02757144","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP14012 After Oral Administration in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2016-03","conditions":"Healthy","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fexuprazan","fed state","fasted state"],"phase":"phase_3","status":"active","brandName":"DWP14012","genericName":"DWP14012","companyName":"Daewoong Pharmaceutical Co. LTD.","companyId":"daewoong-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DWP14012 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":5,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}